InterMune, Inc. (ITMN) recently reported preliminary fourth quarter revenue for its potential blockbuster drug Esbriet. Esbriet is approved in the European Union (EU) for the...(
read more)
InterMune, Inc. (ITMN) posted third-quarter adjusted loss per share of 63 cents, wider than the year-ago loss per share of 44 cents due to higher operating expenses....(
read more)
Class 'B' shares of SunPower Corp. (SPWRA: News ,SPWRB: News ) surged more than 10% in after hours trading after the solar products company said its board of directors has authorized...(
read more)